AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs